Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX®) for cervical dystonia

Allison Brashear, Patrick Hogan, Maureen Wooten-Watts, Albert Marchetti, Raf Magar, John Martin

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Botulinum toxin type A (BoNT/A) is the principal therapy for patients with cervical dystonia. Repeated treatments over many years are required in most cases. This retrospective review evaluates the dose of BoNT/A used to treat cervical dystonia and the interval between treatments during a 2-year observation period. Outcomes data were abstracted from the medical records of 172 patients at 3 different sites who had received BoNT/A between January and December 1998. A total of 1059 treatments were assessed. Mean per-treatment doses throughout the 2-year study ranged from 241.80 to 254.07 units. The mean interval between treatments was 108.48 days during the first year of observation and 114.14 days during the second year. These findings indicate that doses of and intervals between BoNT/A treatments for cervical dystonia were consistent throughout 2 years of observation.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalAdvances in Therapy
Issue number1
StatePublished - Jan 1 2005
Externally publishedYes


  • Botulinum toxin type A
  • Cervical dystonia
  • Spasmodic torticollis

ASJC Scopus subject areas

  • Pharmacology (medical)


Dive into the research topics of 'Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX®) for cervical dystonia'. Together they form a unique fingerprint.

Cite this